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Sphingolipid bioactivities in the respiratory airways and the roles of the proteins that handle them have been extensively
investigated. Gas or inhaled particles or microorganisms come into contact with mucus components, epithelial cells, blood
barrier, and immune surveillance within the airways. Lung structure and functionality rely on a complex interplay of polar and
hydrophobic structures forming the surfactant layer and governing external-internal exchanges, such as glycerol-phospholipids
sphingolipids and proteins. Sphingolipids act as important signaling mediators involved in the control of cell survival and stress
response, as well as secreted molecules endowed with inflammation-regulatory activities. Most successful respiratory infection
and injuries evolve in the alveolar compartment, the critical lung functional unit involved in gas exchange. Sphingolipid altered
metabolism in this compartment is closely related to inflammatory reaction and ceramide increase, in particular, favors the switch to
pathological hyperinflammation.This short review explores a fewmechanisms underlying sphingolipid involvement in the healthy
lung (surfactant production and endothelial barrier maintenance) and in a selection of lung pathologies in which the impact of
sphingolipid synthesis and metabolism is most apparent, such as acute lung injury, or chronic pathologies such as cystic fibrosis
and chronic obstructive pulmonary disease.
1. A Brief Overview on Sphingolipids within
the Lung Environment
The interest in sphingolipid presence and bioactivities in the
respiratory airways has produced a steady number of reports
since the 1970s. However, a host of publications in the last
few years have provided an increasingly detailed picture of
the role played in the lungs by this class of lipids and by the
proteins that handle them. As vital respiratory organs that
mediate air-blood gas exchanges, lungsmust undergo delicate
and tightly controlled developmental transitions. Antenatally,
a 20-week human fetus displays lungs that have branched
to generate all airways, but it is not before ∼28 weeks of
gestation that alveolarization begins fromprimordial saccular
structures and type I alveolar cells differentiate from the
cuboidal epithelium. Concomitantly, at this stage endothelial
cells shape the alveolar capillary bed and type II alveolar cells
appear, to demarcate alveolar septal junctions. Type II cells
start producing surfactant, which accumulates to increasing
concentrations by term. The initiation of autonomous venti-
lation at birth represents a dramatic switch in postnatal lung
function. While throughout gestation a chloride-ion driven
liquid secretion creates a positive pressure that distends the
lungs and stimulates growth, a sudden reversal from net
secretion to net adsorption takes place at birth under the
effect of O
2
and hormones (epinephrine, glucocorticoids,
and thyroid hormones), enabling the rapid elimination of
lung liquid. From this moment on, lung lumen will maintain
a low-level chloride-ion based liquid secretion to generate
a surface liquid layer, known as surfactant and formed by
specific secreted lipids and proteins, and a robust absorptive
capacity will prevent alveolar flooding and edema.
Equally important, being permanently exposed to
inhaled particles andmicroorganisms from birth, pulmonary
immunity must be tuned to effectively dispose of them, while
minimizing immunopathology to preserve appropriate
gas exchange. Thus, the first-line lung defenses, prior to
immunity, are based on mechanical weapons including
cilia, mucus, and the cough reflex, which concur to prevent
pathogen access to the lower airways and in so doing avoid an
overt inflammatory response.This is one of themajor reasons
why lungs are particularly sensitive to the sphingolipid (and
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other lipids) metabolism equilibrium: pulmonary physiology
relies on lipids for important extracellular activity ensured
by surfactant and consisting of a sphingolipid/glycerolipid
network. Indeed, most successful respiratory pathogens
have evolved the ability to gain access to the lower airways
in the alveolar compartment, the critical lung functional
unit involved in gas exchange. Inherited conditions such
as cystic fibrosis are prone to lung infection, partly as a
consequence of a compromised mechanical clearance. Upon
infection or in sterile inflammatory conditions, adjoining
epithelial and endothelial layers in the alveoli, which with
their fused basal lamina form the next leakproof barrier
against microbes, must become temporarily permeable
to allow leukocyte migration. This way, bone marrow
derived macrophages, neutrophils, and dendritic cells can
enter the extra-epithelial space where they meet a resident
population of yolk sac-derived macrophages. A complex
cross talk between specific cell populations (immune cells,
epithelial cells, endothelial cells, stromal cells, and platelets),
mediators, and coagulation and complement cascades
will orchestrate the immune response and inflammation
from start to resolution. However, disruption of alveolar
integrity may occur in aging and in a number of lung
diseases.
How do sphingolipids fit into the above sketch? As
in most other tissues and organs, in the lung too, sphin-
golipids play a crucial role as signaling molecules as well as
components of membranes and extracellular fluids, in both
normal development/functioning and pathological settings
involving inflammation. A lung-specific action is the one
involving sphingolipids as bothminor structural components
of lipid-protein surfactant and regulators of its synthesis
and release. This short review explores a few mechanisms
underlying sphingolipid involvement in the healthy lung
(surfactant production and endothelial barrier maintenance)
and in a selection of lung pathologies where the impact of
sphingolipid metabolites is most apparent. Drawing upon
recent evidence from studies in humans and in animal
models and in vitro, including those in our laboratory, we
attempt to highlight in particular the reciprocal controls
intertwining sphingolipid metabolism with that of other
bioactive lipids (i.e., glycerophospholipids) and the vicious
circle linking sustained cellular stress and the imbalance of
de novo sphingolipid synthesis, as a significant mechanism
acting in favor of tissue injury and against inflammation
resolution in inflammatory lung diseases. Further, current
therapeutic perspectives in using compounds that target the
sphingolipid pathway for countering development of lung
injury will be discussed. For a more extensive coverage of
additional lung pathologies and the role of sphingolipids
therein, the reader is referred to other recent reviews [1–
4]. In addition, here we shall take for granted the gen-
eral notions about sphingolipid biosynthesis, transport, and
breakdown, which have been extensively treated in many
reviews, and shall just recall those that are relevant to our
narrative.
2. Sphingolipid Synthesis during
Pulmonary Functional Maturation
About five decades ago,we learned of the presence of a layer of
surface lipids, with structural and active signaling roles, con-
sisting of lecithin, dipalmitoyl-lecithin, sphingomyelin, phos-
phatidyl ethanolamine, phosphatidylinositol, phosphatidyl-
glycerol, cholesterol, and small amounts of other lipids, along
with proteins of 18 and 36 kDa (termed surfactant proteins),
beginning to form at 28 days of gestation [5, 6]. This notion
led to the use of a lecithin/sphingomyelin (L/S) ratio, from
amniotic fluids, in the clinical diagnosis of fetal lungmaturity
[7] and in the prediction of neonatal respiratory distress
syndrome RDS caused by an insufficient amount of pul-
monary surfactant [8, 9]. An L/S ratio less than 2.0 indicates a
potential risk of RDS.The risk is nearly 75–80%when the L/S
ratio is 1.5. Experiments conducted in rats demonstrated that
the prenatal development of this surface lipid activity sees
sequentially ordered changes in components, including glyc-
erophospholipids (phosphatidylserine andphosphatidylinos-
itol) [10] together with the sphingolipid sphingomyelin [11].
Similarly, sequential changes in the tissue expression of these
lipid-related enzymes were shown, identified in the micro-
somal fraction of respiratory epithelia and in the alveolar
lavage. During the third trimester, the fetal lung synthesizes
primarily sphingomyelin, and themajority of stored glycogen
is converted to fatty acids and then to surfactant lipids. The
enzymes responsible for the biosynthesis of phosphatidyl
glycerolipids (CTP: Phosphatidate Cytidylyl Transferase and
CDP-Diacylglycerol: Glycerolphosphate Phosphatidyl Trans-
ferase and Phosphatidyl Glycerol Phosphate Phosphatase)
demonstrated a coordinate increase in activity in fetal rat
lung at term when the demand for pulmonary surfactant
increases. A fall in one phospholipid is accompanied by
an increase in another. The same phenomenon is observed
among phospholipids in human amniotic fluid, suggesting a
similar development and further confirming the continuity
between fetal lung secretions and the amniotic fluid. At birth,
the expression of themajor enzymes involved in phosphatidyl
choline synthesis (CTP and CDP) as well as the expression
of Serine Palmitoyl Transferase and Sphingomyelin Synthase
further increases, respectively, in type I [10] and type II
alveolar cells [11]. Ceramide Synthase 5 is the predominant
isoform detected in lung epithelia and its expression is
also upregulated. Concomitantly synthesized at ER [12],
phosphatidylcholine and sphingomyelin are both secreted in
the surfactant, whereas lung tissue, other than surfactant,
contains only small amounts of these phospholipids. It is
noteworthy that sphingolipid and glycerolipid metabolisms
overlap at the enzymatic step where ceramide competes with
diacylglycerol for the phosphocholine (deriving from CDP-
choline or phosphatidylcholine) to give rise to sphingomyelin
(Figure 1). In adult life, enzyme activity reaches a plateau,
and the ratio between the key enzymes of the two pathways,
Serine Palmitoyl Transferase over Glycerol 3-phosphate Acyl
Transferase, is significantly higher in microsomal lung (and
pancreas) than in most other adult rat tissues; accordingly,
the percentage of sphingomyelin is higher in the total phos-
pholipid content in these fractions [13].
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Figure 1: Sphingolipidsmetabolites form a networkwith other inflammatory lipids in the lung. (a) Intracellular and secretory lipids regulating
inflammation in mucus and mucosa. Red: inflammatory lipids and major controlled enzymatic activities. Green: anti-inflammatory lipids
and major controlled enzymatic activities. P, phosphate; FA, fatty acids, Cho, choline; CDP, citidyl diphosphosphate; DAG, diacylglycerol;
TGs, triglycerides; PE, phosphatidyl ethanol ammine; PC, phosphatidyl choline; PAF, platelet activating factor; AA, arachidonic acid;
PGE2, prostaglandins E2; Sph, sphingosine; Cer, ceramide, SM, sphingomyelin; CTT, CTP: Phosphocholine Cytidyl-Transferase; SMase,
Sphingomyelinase, SMS, Sphingomyelin Synthase, and CERS, Ceramide Synthases; SPT, Serine Palmitoyl Transferase; cPLA2, Cytosolic
Phospholipase 2. (b) Ceramide accumulation controls other inflammatory and anti-inflammatory lipids. Red: inflammatory lipids andmajor
controlled enzymatic activities. Green: anti-inflammatory lipids and major controlled enzymatic activities.
Fetal lung maturation allows protection from mater-
nal infection, but this maturation process can be altered
by pathogens [14]. Surfactant components generally de-
crease harmful inflammatory responses [15]. Preterm labor-
inducing inflammatory ligands (interleukin-1 or lipopolysac-
charide) cause a robust induction of the surfactant complex
in order to lower the risk of respiratory distress syndrome
(RDS). Data from clinical studies suggest that surfactant can
be used successfully in neonates with congenital pneumo-
nia, due to a comprehensive contribution by surfactant to
host defense from pathogens [16, 17]. However, such trials
obtained mixed results and much evidence in animal stud-
ies demonstrates that surfactant therapy may also enhance
inflammation and reduce the ability of macrophages to clear
pathogens [18–20], raising the hypothesis that surfactant
physiologic activity relies on a complex equilibrium, whose
alteration drives a pathological setting. Thus, an unbalanced
sphingolipid metabolism impact on surfactant composition
and pulmonary function as well as pharmacological inter-
vention aimed at regulating sphingolipids mediators can
promote or block surfactant production. A more extensive
comprehension of sphingolipid moiety of surfactant would
help to identify therapies or adjuvants for most lung diseases.
3. A First Glance at the Small Picture:
Sphingolipid Molecules Take Part in Airway
Cell Signaling in Inflammatory Responses
Before dealing with pulmonary disease, we should review
better the evidence collected for sphingolipid signaling in
lung-derived cell cultures under pathologic stress. The very
first evidence of sphingolipid involvement in lung inflamma-
tion concerns the production of autoantibodies against gly-
cosphingolipids (aGM1 andGM1b) in response to pulmonary
infection with Mycoplasma pneumonia [21]. Damaged or
regenerating respiratory epithelial cells, typical of cystic
fibrosis or lungs suffering from emphysema, exhibit increased
expression of receptors for sialylated glycosphingolipids [22],
which are recognized by Gram-positive and Gram-negative
organisms. Upon engagement, these receptors activate the
inflammatory signaling cascades of the acute innate phase
[23]. Moreover, alveolar macrophages undergo maturation
steps, showing surface expression of aGM1 [24, 25].
In addition to infection, it is possible to reproduce lung
inflammation, in an in vitro setting, by stressing cells with
oxidative agents (e.g., hydrogen peroxide), which represent
the by-products of inflammatory damage. Alternatively, cells
can be stressed directly with inflammatory mediators or
by blocking trophic and prosurvival stimuli, which are
dramatically reduced in pulmonary low oxygen pathological
conditions (i.e., by inhibiting Vascular Endothelium Growth
Factor (VEGF) receptor signaling). Most of the in vitro
evidence suggests that ceramide can be pharmacologically
targeted to reduce reactive oxygen and nitrogen species and
inflammatory damage in airway cells. In 2000, Chan and
coauthors demonstrated, at a molecular level in the human
airway epithelial cell line (HAE), the dependency of hydro-
gen peroxide-induced apoptosis on ceramide generation
following the activation of the glutathione-sensitive neutral
Sphingomyelinase [26, 27]. A few years later, Goldkorn and
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his group demonstrated that hydrogen peroxide upregu-
lates neutral Sphingomyelinase 2 and consequently increases
ceramide levels in human airway epithelial cells [28, 29]. IL-
8 plays a pivotal role in lung injury, serving as a recruiter
for neutrophils. Neutrophil invasion causes a massive release
of oxygen radicals, proteases, and other toxic moieties,
responsible for the subsequent tissue destruction and loss
of barrier function, leading to pulmonary edema, intrapul-
monary shunt, and hypoxemia hallmarks. IL-8 neutralization
can be envisaged as a therapeutic approach [30]. Glutathione
inhibition of neutral Sphingomyelinase counteracts part of
the oxidative stress-induced signaling (p38 activation, inhi-
bition/degradation of the bound phosphatase calcineurin)
that sustains IL-8 transcriptional activation [31]. Apart from
reactive oxygen species, such as hydrogen peroxide, reactive
nitrogen species (RNS) are involved in the pathophysiol-
ogy of inflammatory lung diseases. NO exposure (via NO
donors) was able to induce ceramide accumulation but not
apoptosis in airway epithelial cells, by stimulating Ceramide
Synthases. This accumulation was inhibited by fumonisin
B1 (inhibitor of Ceramide Synthases) [32]. According to the
notion that different pools of ceramide can be raised by
different stress inducers and take part in specific responses
[33], not only neutral Sphingomyelinase but also the activity
of Ceramide Synthases is therefore modulated in airway
epithelia inflammation.The combined presence of high levels
of NO and superoxides generated peroxynitrite (ONOO(−)),
which is responsible not only for the ceramide increase but
also for apoptosis induction. Such apoptosis was prevented
by silencing acid Sphingomyelinase [34].
Taken together, these findings support the hypothesis
that the inflammatory stress in airway epithelia, driven by
oxygen and nitrogen oxidative species, modulates different
pools of ceramide, possibly involving its de novo synthesis
until the stress is tolerated and evolving to Sphingomyelinases
activation to induce apoptosis.
Ceramide can be deacylated by Ceramidases to give
rise to the toxic sphingosine, which can be immediately
phosphorylated to sphingosine-1-phosphate. Among all the
sphingolipids, sphingosine-1-phosphate is a minor species
in terms of intracellular concentration but is endowed with
potent proliferative and prosurvival activity. The high level
of plasma sphingosine-1-phosphate, bound either to albumen
or to lipoproteins, has important homeostatic functions in
the maintenance of vascular integrity [35] and its gradient
is crucial for immune cell trafficking during inflamma-
tory reactions [36]. The role of sphingosine-1-phosphate in
inflammation is partially controversial. Although in vivo it
exerts mainly an anti-inflammatory role (discussed in the
following sections), a few reports demonstrate proinflam-
matory activities of this lipid mediator. H441 lung epithe-
lial cell treatment with exogenous sphingosine-1-phosphate
induced an increase in IL-8 mRNA and its secretion.
TNF𝛼 can also activate Sphingosine Kinase [37, 38], and
sphingosine-1-phosphate leads to IL-8 gene expression via
ERK and p38 MAPK activation and increased AP-1 inflam-
matory transcriptional activity in alveolar macrophages
[39]. Thus sphingosine-1-phosphate recapitulates the action
previously ascribed to ceramide and possibly exerted by
sphingosine-1-phosphate. A putative explanation may be that
sphingosine-1-phosphate, either supportive or alternative to
ceramide, could exert different actions not only on cell
culture treatment versus in vivo but also in physiological
and protective inflammatory responses [26], as opposed to
pathological inflammation.
Human pulmonary artery endothelial cells effectively
utilize exogenous sphingosine-1-phosphate as a prosurvival
and permeability regulator, via extracellular conversion to
sphingosine by Lipid Phosphate Phosphatase-1 and uptake
of sphingosine followed by intracellular phosphorylation by
Sphingosine Kinase-1 [40, 41]. VEGF receptor is engaged
by a trophic factor required for the survival of endothe-
lial cells and abundantly expressed in the lung [42]. The
inhibition of VEGF receptor initiates apoptosis and alveolar
destruction, morphologically resembling emphysema, and it
is concomitant to an increased ceramide synthesis in the
alveolus [43, 44]. FTY720, a sphingosine analogue which
can be phosphorylated [45], acts as a downregulator of
sphingosine-1-phosphate receptor 1 by inducing its ubiq-
uitination, internalization, and degradation [46, 47], but
it was also proved to directly inhibit Ceramide Synthases
activity in human pulmonary artery endothelial cells [48].
Consequently FTY720 may at the same time target ceramide
synthesis and sphingosine-1-phosphate signaling, which is
downstream of ceramide catabolism. A contrasting but inter-
esting report supports the hypothesis of a complex and
fine regulation of ceramide signaling pools in which TNF𝛼-
induced ceramide in lung epithelial cells is necessary to
downregulate IL-8 synthesis. In line with previously reported
ceramide activation of the Protein Phosphatase 2A (PP2A)
[49] and ceramide impairment of the binding of noncompet-
itive biological inhibitors of PP2A [50], Cornell et al. reported
that TNF𝛼-induced ceramide, in respiratory epithelial cells,
activates PP2A, which is responsible for dephosphoryla-
tion/inactivation of MAPK pathways (JNK, p38, and ERK)
and consequently for the inhibition of their downstream NF-
kB promoter activity. This would explain the downmodu-
lation of the IL-8 transcription. The authors showed that
both desipramine (inhibitor of acid Sphingomyelinase) and
fumonisin B1 pretreatments (for a few hours) block the
initial ceramide increase upon TNF𝛼 receptor engagement,
indicating a double pathway leading to ceramide accumu-
lation from de novo synthesis and from the sphingomyelin
cycle. This initial ceramide wave is, in their hypothesis,
important in a feedback regulation of inflammatory signaling
and its absence enhances IL-8 release [51]. These apparently
contrasting data, suggesting a ceramide role of “inflammation
homeostasis keeper,” can be explained if we consider an
overall picture of a physiological inflammatory setting versus
chronic inflammatory pathology. Acute stimulation of early
inflammatory inducers, such as TNF𝛼, may trigger a con-
trolled remodeling of sphingolipid mediators, during which
ceramide can be driven intometabolic transformation such as
the sphingomyelin cycle or the phosphorylation to ceramide-
1-phosphate. The latter, involved in inflammation with con-
trasting evidence [52], was shown to mediate TNF𝛼-induced
IL-10 production, thus representing the missing link that
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relates proinflammatory to anti-inflammatory/physiological
inflammation resolution response [52, 53].
In this line of thinking, an initial ceramide-driven
reaction to inflammation could be aimed at inflammation
resolution, but it is conceivable that deregulation of ceramide
metabolism enzymes, due to excessive stimuli and stress,
can become an effector arm that easily pushes the whole
inflammatory machine to collapse into pathological chronic
inflammatory signaling.
4. Sphingolipid Metabolites Form a Network
with Other Inflammatory Lipids in the Lung
PAF is a potent lipid mediator which is involved in asthma,
sepsis, and acute lung injury, responsible for vasocon-
striction, bronchoconstriction, vascular permeability, and
pulmonary and extra-pulmonary edema formation. PAF-
induced increase in vascular permeability is mediated by
PGE2 and ceramide, derived from acid Sphingomyelinase
activation, in endothelial cells [54, 55]. On the other side,
PAF-induced activation/maturation of macrophages during
inflammation was related to de novo ceramide synthesis
induction [56]. Moreover, the Sphingomyelinase activation
and ceramide accumulation promote Cyclooxygenase 2
expression and its release of PGE2 [57].
Being a major surfactant component, phosphatidyl
choline is largely used in clinical therapy as a potent anti-
inflammatory agent for intestinal mucosa protection [58, 59].
In airway epithelia cells, the interrelation of sphingolipids
and glycerolipids metabolism was assessed by demonstrating
that cytokine-induced catabolism of sphingomyelin, related
to the inflammatory ceramide release, and the inhibition
of the anti-inflammatory phosphatidyl choline synthesis
are directly dependent on one another, suggesting that a
complex program of lipid adjustment is targeted to ini-
tiate inflammatory response. TNF𝛼-derived ceramide and
sphingosine inhibit Phosphatidyl-Choline: Ceramide Phos-
phocholine Transferase (Sphingomyelin Synthase) [60, 61],
blocking the “consumption” of phosphatidyl-choline to form
sphingomyelin and diacylglycerol. At the same time, in
H441 cells, TNF𝛼-induced ceramide reduces phosphatidyl
choline synthesis, probably because of its inhibition of CTP:
Phosphocholine Cytidylyl-Transferase (CTT), which is the
rate-limiting enzymatic step in de novo phosphatidyl choline
synthesis [60, 61]. In this view, the inflammatory stimulus
TNF𝛼 raises ceramide release, via Sphingomyelinase acti-
vation. Ceramide activates cytosolic PLA2, thus increasing
lysophosphatidyl choline, which on the contrary is a proin-
flammatory mediator [62] and inhibits the phosphatidyl
choline synthesis (CTT activity). The arachidonic acid,
released by cPLA2 upon lysophosphatidyl choline formation,
stimulates the synthesis of leukotrienes, which in turn raise
intracellular Ca2+ levels and complete the activation of cPLA
2
[60], as well as lysosomal phospholipases [39] (Figure 1).
Interestingly, the overexpression of Ceramide Synthase 5,
the predominant Ceramide Synthases isoform detected in
lung epithelia, also reduced phosphatidyl choline synthesis,
but maximal inhibition was achieved when Ceramide Syn-
thase 5 was coexpressed with a plasmid encoding a neutral
Sphingomyelinase, enhancing sphingomyelin hydrolysis [63].
Thus, the modulation of sphingolipid metabolism drives the
formation of glycerolipids inflammatory molecules as well as
the eicosanoids family of inflammatory lipids. Altered sur-
factant is undoubtedly related to inflammatory stress within
the lungs. Inflammatory cytokines regulate the alveolar pool
of sphingomyelin. Sphingomyelin hydrolysis, induced upon
inflammation, causes a twofold increase in the amount of
surfactant-associated ceramide, tending to decrease the sph-
ingomyelin mass, thus impairing the biophysical properties
of the alveolar surfactant film [64]. Moreover, ceramide can
interfere with surfactant production and release. All these
lipids and surfactant components are secreted by type II
pneumocytes by regulated exocytosis of secretory vesicles,
termed lamellar bodies. The fusion of lamellar bodies with
the plasma membrane is inhibited by treatment with the
ceramide analogue C2-ceramide, which inhibits phospho-
lipase D activity [65]. Moreover, in H441 airway epithelial
cells, ceramide decreased SP-B surfactant production. This
was shown to occur by a unique ability of ceramide to bind
to a region located within the −233/−80 bp region of human
SP-B promoter. Ceramide binding was shown to reduce the
transactivation capability of thyroid transcription factor 1
(TTF-1/Nkx2.1), a key factor for SP-B promoter activity [66].
An overall view of sphingolipid interaction with other lipids
and of their inflammatory and anti-inflammatory activities is
provided in Figures 1(a) and 1(b).
5. Sphingolipid in Pulmonary
Inflammatory Pathologies: Acute and
Chronic Inflammation Are Sustained by
Sphingolipid Mediators
Pathological inflammation in the lung involves surfactant
and mucus production, epithelial cell reaction, endothelial
permeability, immune response, parenchyma, and matrix
damage. The major outputs are leukocyte infiltrate, releas-
ing damaging molecules such as radicals and proteases;
tissue edemas and fibrosis remodeling; small terminal air-
way damage (bronchiolar loss) with low oxygen-hypoxia
induction; capillary damage and hypertension; necrosis and
emphysema. In the following paragraphs we will review the
involvement of sphingolipid mediators and the adjustments
of sphingolipid metabolism in the setting of pulmonary
inflammation, focusing only on acute lung injury and on two
major chronic diseases, namely, cystic fibrosis and chronic
and obstructive pulmonary disease.
5.1. Pulmonary Inflammation and Acute Respiratory Dis-
tress Syndrome (ARDS). Pulmonary inflammation, generally
known as Adult Respiratory Distress Syndrome (ARDS),
occurs in individualswho sustain systemic or localized insults
(sepsis, aspiration of toxins, emboli, circulatory collapse, and
metabolic neurological hematological disorders) that cause
diffuse lung injury. Acute lung injury (ALI) is themost severe
form. The major event is fluid leaking into the lungs from
damaged capillaries (edema). Disappointing results from
therapeutic approaches, targeting known involved mediators
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such as TNF𝛼, PAF, or PGEs, suggest that several parallel and
interacting mechanisms are involved. Sphingolipid altered
metabolism was shown to take part in this pathological
process.
As early as 1985, Merrill and his collaborators noticed a
significant decrease in sphingomyelin in the lungmicrosomal
fraction of rats maintained in elevated versus normal oxygen
levels [67]; later, alteration in oxygen supply (hyperoxia) was
shown to be a potent cause of ceramide accumulation and of
lung injury and inflammation [68–70]. This early evidence
shed light on the hypothesis, largely validated later on, that
sphingolipids are modulated during inflammatory processes
relating to airway oxygenation and may actively take part in
inflammation responses.
Besides surfactant phospholipids, bronchoalveolar lavage
from ARDS patients contains a significant amount of
ceramides and glycosphingolipids (lactosyl ceramides and
paraglobosides), appearing during lung injury, that are
present just in traces in healthy people [71]. The glycosph-
ingolipids take part in damage because they are able to
inhibit the surfactant system in vitro by increasing surfactant
tension obtainable at minimum bubble size [71]. Ceramide
derivatives are markedly elevated in bronchoalveolar lavage
fluid of patients with ARDS [71] and plasma ceramide levels
correlate with mortality [72].
Go¨ggell and coworkers extensively analyzed the role
of ceramide in lung edema, demonstrating that ceramide
accumulation in lung tissue and fluids, upon acid Sphin-
gomyelinase increased activity, is an important cause of
edema formation [73]. Mice treated with PAF developed
pulmonary edema which was reduced by ∼50% in acid
Sphingomyelinase deficient animals. A further decrease was
obtained if deficient animals were treated with acetylsali-
cylic acid, indicating a common involvement of acid Sph-
ingomyelinase and cyclooxygenase in the pathogenesis of
pulmonary edema. Moreover, the perfusion of rat lungs
with TNF𝛼 or PAF rapidly induced an increased ceramide
concentration in the alveolar fluid, suggesting increased
activity of extracellular acid Sphingomyelinases. Antisera
against ceramide as well as the pharmacological inhibitors of
the membrane cycle sphingomyelin/ceramide (xanthogenate
D609 for Sphingomyelin Synthase and imipramine for
acid Sphingomyelinase) prevented PAF-triggered pulmonary
edema. Nonetheless, inhibition of ceramide release from the
plasmamembrane had no effect on other PAF actions, such as
reduction in pulmonary vasoconstriction and bronchocon-
striction.The authors exclude that ceramide may derive from
a biosynthesis pathway because fumonisin B1, an inhibitor of
Ceramide Synthase, had no effect on pulmonary edema. In a
neonatal piglet model of airway inflammation, induced upon
repeated lavages, surfactant plus desipramine administration
prevented edema, inflammatory marker upregulation, leuko-
cyte alveolar influx, and increase in ceramide content. Similar
results were obtained in acid Sphingomyelinase deficient
mice treated with surfactant, which were protected from
inflammation unlike Sphingomyelinase-expressing control
animals [74].
Acute pulmonary injury can be modeled by bleomycin-
induced inflammation and fibrosis inmice. Such pathological
consequences correlated with the rapid activation of acid
Sphingomyelinase, and injury was markedly attenuated in
the absence of the enzyme (knockout mice). Along with
the elevated acid Sphingomyelinase activity, there was an
increase in acid ceramidase activity, which was sustained
for up to 14 days after bleomycin treatment, suggesting a
possible bioactivity of the induced accumulation of sphingoid
back-bone mediators such as sphingosine and sphingosine-
1-phosphate. Consistently with this hypothesis, bleomycin
treatment induced acid Sphingomyelinase and acid Cerami-
dase increased activity and accumulation of sphingosine-1-
phosphate in NIH3T3 fibroblasts [75]. Nonetheless, the for-
mation of sphingosine-1-phosphatewas able to counteract the
inflammation-induced endothelial permeability [76, 77] and
pharmacological use of its analogues (FTY720, s-FTY720-
phosphonate, and SEW2871) was proposed as a therapeutic
approach in ALI [78].
Although these data suggest a key role for acid Sph-
ingomyelinase activation and ceramide formation to cause
edema, studies in human airway epithelial cells have shown
that neutral Sphingomyelinase, but not acid Sphingomyeli-
nase, is activated to induce cell death by inflammatory stress,
such as cigarette smoke [28]. Hyperinflammation, such as
LPS treatment, is associated with induced suppression of
spontaneous neutrophil apoptosis, whose peculiarity is to
provide for their own suppression, being short-lived dif-
ferentiated cells. A massive and uncontrolled presence of
neutrophils in the lung contributes to inflammation, thus
entering a pathological vicious cycle. Lin and colleagues
demonstrated significantly higher ceramide levels in alveolar
neutrophils from ARDS patients than in those from healthy
subjects, indicating an association between inflammatory
granulocytes and increased ceramide level, specifically in
the alveolar areas [79]. These authors showed that Sph-24
(neutral Sphingomyelinase inhibitor) and SKI-II (Sphingo-
sine Kinase I inhibitor, triggering the enzyme lysosomal
degradation [80]) antagonized the antiapoptotic effect of LPS
[79]. Interestingly the acid Sphingomyelinase inhibitor CHL
(inducing the enzymes lysosomal degradation [81]) had no
effect on the regulation of neutrophil apoptosis in response
to LPS stimulation.
Thus ceramide is one of the required triggers of inflam-
mation, endothelial leaking, and edema in pulmonary injury;
the acute inflammatory stress would cause a burst in sph-
ingolipid catabolism, both at the acidic lysosomal compart-
ment and at the plasma membrane neutral compartment,
thus involving multiple inflammatory signaling. Sphingo-
sine and sphingosine-1-phosphate accumulation may derive
from lysosomal-related ceramide formation and possibly
contribute to inflammation with diverse effects depending
on the cell type and sphingosine-1-phosphate increase may
impair neutrophils spontaneous apoptosis. The underlying
idea, stemming from these reports and suggested by von
Bismarck and colleagues, is that it may be possible to
create a “fortified surfactant preparation,” enriched in anti-
inflammatory lipids and/or enzyme inhibitors (i.e., Sphin-
gomyelinases inhibitors), with therapeutic activity against
newborn lung inflammation.
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5.2. Cystic Fibrosis. Cystic fibrosis (CF) is the most com-
mon life-threatening recessive genetic disease in the Cau-
casian population, affecting approximately 70,000 individuals
worldwide, withmedian predicted life expectancy around the
age of 40. This genetic disorder, caused by a mutation of the
CF transmembrane conductance regulator (CFTR) gene, is
mostly characterized by recurrent lower respiratory infec-
tions, exocrine pancreatic insufficiency (85% of patients), and
increased electrolyte concentration in sweat. The CFTR gene
encodes a member of the ATP-binding cassette transporter
superfamily, involved in multidrug resistance. The encoded
protein functions as a chloride/carbonate exchange channel,
driving anions through different lipid-encased cellular com-
partments [82].
CFTR resides inmany endosomalmembranes, trafficking
to the epithelial surface and back again; it is localized within
lipid rafts and alters membrane lipid composition and in
particular ceramide-driven membrane lipid rafts [83, 84].
CFTR mutation can be considered per se as a real cause
of inflammatory disease and, even in sterile condition, CF
fetuses exhibit atrophy or metaplasia and absence of villi.
Moreover, the tracheal epithelium in infants and young
children exhibits dilated airways with thicker epithelial walls
[85, 86]. Human CF fetus allografts of lung small airways into
mice with severe combined immunodeficiency (missing lym-
phocytes and NK cells) stimulate an immediate neutrophil
over response and tissue damage, suggesting that innate
immunity is hyperactivated even in the absence of infection
[87].
It was reported that wild type CFTR, possibly acting
as a scavenger, uptakes sphingosine-1-phosphate and the
structurally related lipids dihydrosphingosine-1-phosphate
and lysophosphatidic acid, thus modulating cell responses
to these lipids. In the presence of CFTR, sphingosine-1-
phosphate intake increases, thus leaving less ligand available
for interaction with sphingosine-1-phosphate receptor and its
signaling towards proliferation, migration, and angiogenesis.
This would explain the abnormal angiogenesis, responsible
for fibrosis, in CF disease, due to a higher availability of
sphingosine-1-phosphate and to its stimulation of excessive
angiogenesis in response to inflammation [88, 89].
CFTR inhibitors GlyH-101 and CFTRinh172 caused a
dose-dependent increase in permeability of the pulmonary
or bronchial endothelial monolayer. Increased endothelial
sphingosine-1-phosphate, either by exogenous treatment or
by endogenous inhibition of its degradation, significantly
improved the barrier function inCFTR-inhibitedmonolayers
[90].
In addition to the role of sphingosine-1-phosphate in CF,
themost significant aspect ofCFTRdysfunction, according to
the published papers overall, is an imbalance of sphingolipid
homeostasis, due to ceramide release from sphingomyelin
within the membranes [91] and to a disease-related increase
in ceramide synthesis [83, 92].
A considerable amount of evidence indicates that
ceramide may be a pharmacological target in CF, since
its accumulation significantly contributes to sustaining
hyperinflammation and inability to fight lung infection. The
first evidence of lipid and sphingolipid imbalance in CF was
reported in the late seventies with the analysis of various
lipids, including glycosylated ceramides, in the bronchial
lavage and sputum of CF patients [93, 94]. Ceramides,
mainly bearing C16:0, C18:0, and C20:0 acyl chains, were
shown to accumulate progressively in the lower airway, as
the disease advanced, in cystic fibrosis patients, compared
with pulmonary hypertension and emphysema patients
and healthy donors. Ceramide accumulation correlated
with infiltrate presence (neutrophils) [95]. UIrich and
coauthors demonstrated extensive inflammation and tissue
remodeling in the alveolar tissues from CF patients with
advanced lung disease, showing increased myofibroblasts,
intercellular adhesion of molecule-1 and collagen expression,
and decreased elastin fibers. In these patients alveolar type II
cells were markedly stained with anti-ceramide antibodies,
demonstrating a close association between inflammation
ceramide accumulation and damage within the lower airways
[96].
This evidence contrasts with Becker and coworkers’
reported data, showing a decrease in ceramides and docosa-
hexaenoic acid (DHA) and an increase in arachidonic acid
(AA) content in CF plasma compared with healthy controls.
The reduced levels of circulating ceramides, showed by
the authors, may be ascribed to CF patients’ low plasma
HDL, LDL, and total cholesterol levels, due to malab-
sorption and altered liver function [97]. In these authors’
hands, the administration of fenretinide to patients cor-
rected ceramide and other lipids levels [98]. Fenretinide
is a known chemotherapeutic agent that modulates sph-
ingolipids by inhibiting a dehydrogenation reaction that
forms ceramide, thus accumulating dihydroceramide. Data
supporting a mechanism which could explain the plasma
ceramide upregulation upon fenretinide treatment are miss-
ing. However, fenretinide has different intracellular targets
leading to apoptosis that are not related to the inhibition of
dihydroceramide desaturation and that may in turn cause
ceramide release from apoptosis-related Sphingomyelinases
activation [99].
A more thorough knowledge of sphingolipid signaling in
CF is obtained from studies in animal models. It is worth
noting that both circulating and pulmonary lipid analyses
must be obtained only in normal diet fed CF animal models.
These can be either low CFTR expressing or CFTR knockout
but corrected for wild type CFTR expression in the gut only
[83, 100]. In these models, most reports confirm the hypoth-
esis that accumulation of ceramide in the lung promotes
apoptosis, DNA deposition, and granulocyte hyperactivity,
thus facilitating infection [91].
The alveolar epithelium comprises two main cell types:
alveolar type I and alveolar type II cell. Type I cell is a complex
branched cell withmultiple cytoplasmic plates that are greatly
attenuated and relatively devoid of organelles; these plates
represent the gas exchange surface in the alveolus. On the
other hand, type II cell responds to damage of vulnerable
type I cell by dividing and acting as a progenitor cell for both
type I and type II cells. In addition, it synthesizes, stores, and
releases pulmonary surfactant into the alveolar hypophase,
where it acts to optimize conditions for gas exchange [101].
Alveolar spaces are primarily involved in inflammatory
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responses, being endowed with extended capillary distri-
bution and resident phagocytes. Moreover, alveolar epithe-
lial cells cooperate with alveolar macrophages in immune
response and pathogen clearance, by expressing TLRs upon
infection [102]. The greatest accumulation of ceramide in
CF animals is in the lower airways and, specifically, in
alveolar type II cells [96], although a marked accumulation
of ceramide was also seen in tracheal and intestinal epithelial
cells of low CFTR expressing (solid diet fed) mice [103].
The increased ceramide concentration in alveolar epithelia
may significantly contribute to inflammatory signaling and
impaired pathogen clearance exerted by these particular
cells, addressing the lower airways as the specific therapeutic
targets in chronic lung inflammation and infection (Caretti
A. and Signorelli P. unpublished data).
Teichgra¨ber et al.’s lab demonstrated an accumulation
of ceramide located in intracellular vesicles (not restricted
to lysosomes) in CFTR deficient respiratory epithelial cells.
According to these authors, CFTR deficiency increases the
pH of this vesicular compartment (around pH 6), causing
an imbalance between the enzymatic activities of acid Sphin-
gomyelinase and Ceramidase. While acid Sphingomyelinase
activity was partially compromised by the pH variation, acid
ceramidase activity was dramatically reduced by 90%. Such
alteration of activities ensures a release of ceramide from
sphingomyelin and then overcomes its clearance by degrada-
tion [91]. The same group, based on previously reported data
[104, 105], claimed that CFTR deficiency increases the pH of
secretory vesicles produced by alveolar macrophages upon P.
aeruginosa infection, correlating with a reduced production
of ROS and reduced bactericidal activity and with ceramide
intracellular accumulation and altered lipid raft formation on
the plasma membrane [106].
In support of the ion imbalance hypothesis in CFTR
deficiency, Noe et al. suggested that increased pH and
ceramide are responsible for aberrant angiogenesis, lead-
ing to fibrosis in CF disease. Impairment of physiologi-
cal apoptotic response to stress in the endothelium may
lead to abnormal angiogenesis and chronic inflammation.
Ceramide is a key regulator of survival and apoptosis in
endothelial cells. Oxidative stress, as fromhydrogen peroxide,
induces ceramide increase mainly via de novo sphingolipid
synthesis in endothelial cells. Inhibition by CFTR(inh)-172
of endothelial cell channel activity prevented the increases
in the ceramide: sphingosine-1-phosphate ratio induced by
hydrogen peroxide, impairing caspase activation and apopto-
sis [107], thus promoting aberrant proliferation under stress
and pathological angiogenesis. This evidence would suggest
that CFTR deficiency modulates ceramide by altering the pH
of intracellular compartments, leading to diverse outcomes
according to the cell type.
In line with the hypothesis of an increase in ceramide
due to a pH dependent inactivation of acid ceramidase;
sphingosine presence on the surface of nasal epithelial cells
from CF patients was shown to be almost undetectable
(by means of an anti-sphingosine antibody), whereas it is
abundantly expressed on the luminal surface of human nasal
epithelial cells obtained from healthy individuals. Similar
results were obtained in bronchial cells from CF mice. With
the aim of demonstrating that sphingosine deficiency may
favor bacterial colonization, the inhalation of purified acid
ceramidase or sphingosine or its analogue FTY720 was
obtained in pulmonary infected CF mice. The treatment not
only corrected the anomalous absence of mucosal sphin-
gosine in CF murine airways but also significantly reduced
increased ceramide levels and allowed an effective response
against lung colonization by P. aeruginosa. These results
were obtained by treating either prior to or after infection,
indicating this therapy as preventive aswell as curative against
bacterial infection [108]. Although the idea of a reservoir
of mucosal sphingosine as a toxic compound, to be spent
against pathogens invasion, is attractive, the hypotheses put
forward by these authors will certainly require further studies
for validation. A major issue that needs to be cleared up, in
our opinion, is as follows: given that sphingosine is a toxic
compound for eukaryotic cells, how is it possible to obtain
beneficial effects in terms of killing bacteria by exogenous
administration, avoiding damage to the host?
Although this “pH theory” would fit the above reported
published data, by means of CFTR overexpression systems
and loss-of-function studies, other investigators reported that
neither the secretory (Golgi and TGN) nor the endocytic
organelles (endosomes, lysosomes, and phagosomes) display
a CFTR-dependent acidification defect (revised in [109]),
questioning the technical methods previously used to mea-
sure intracellular pH [110]. These latter studies clearly show
thatCFTR-independent andoverall counter-ion permeability
was remarkably higher than the passive proton permeability
of endosomes, lysosomes, and phagolysosomes of respiratory
epithelia and primary or immortalized mouse macrophages.
Therefore, CFTR activation cannot interfere with the endo-
somal pH regulation [109] and ceramide modulation should
derive from mechanisms other than pH deregulation of
Ceramidase.
In line with the observations arising from their patients’
studies, Teichgra¨ber and his coworkers investigated the
hypothesis of a hyperactivation of acid Sphingomyelinase in
CF animal models. Although the baseline activities of acid
Sphingomyelinase and acid Ceramidase in lung homogenates
from CFTR deficient animals are equivalent to those in
control mice [91], they achieved partial inhibition of the
activity of acid Sphingomyelinase either by intraperitoneal
injection of amitriptyline or by heterozygous deficiency
for acid Sphingomyelinase and observed reduced airway
inflammation, phagocyte recruitment, and susceptibility to
infection by Pseudomonas aeruginosa [91, 111].
Other authors confirm the long term efficacy of
amitriptyline to inhibit the robust burst of inflammatory
response in CFTR deficient (gut corrected) mice subjected
to Pa-LPS-induced acute lung injury. In such a model,
the authors also demonstrated an early anti-inflammatory
activity of fumonisin B1, which is lost at a longer time.
Although not explained, the early anti-inflammatory effect
of this last inhibitor can be related to its ability to activate
Sphingosine Kinase-1 [43, 112, 113] and, therefore, to the
upregulation of sphingosine-1-phosphate levels. Moreover
we believe that fumonisin B1 can also reduce a burst of
ceramide arising from de novo synthesis activation in
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inflammation [92], which in turn sustains the activation of
Sphingomyelinase(s) [44]. Nonetheless, the inhibition of
Ceramide Synthase by fumonisin B1 is associated with the
inevitable mounting, over time, of toxic sphingoid bases.The
bioactivity of these metabolites may later on overcome the
initial anti-inflammatory action of the inhibitor [114].
CFTR deficiency in mice results in the upregulation of
CD95, crucially involved in aseptic inflammation, bronchial
cell death rate, and susceptibility to infection. CD95 is
activated upon increase of membrane ceramide concentra-
tion; CD95 also contributes to stimulating further ceramide
release, possibly concurring in the inflammatory pathology
of CF [97].
Whereas CF mice exhibit upregulation of inflammasome
components and an altered presence of tight junction pro-
teins in lung epithelia, knocking out (heterozygous gene
deletion) acid Sphingomyelinase in the same CF mice model
resulted in animals similar to the healthy control mice [115].
In addition, CF mice exhibit increased rates of cell death,
increased cytokines concentration, and ceramide levels in
the trachea and intestine. The inhibition of acid Sphin-
gomyelinase activity ensured the concomitant normalization
of cell death, inflammatory cytokines, and ceramide concen-
tration in these body districts [103]. These findings suggest
that ceramide plays a crucial role in inflammation and in
increased rates of cell death in several organs of cystic fibrosis
mice.
The “take home message” derived from the above
reported findings is that ceramide and/or its metabolite
sphingosine play a crucial role in inflammation and increased
rates of cell death in several organs of cystic fibrosis mice
[103]. The encouraging results led to the initiation of clin-
ical trials with amitriptyline: the drug was administered to
patients 25–50mg/d twice daily for 28 days. Increased FEV1
and reduced ceramide in nasal and lung cells were observed,
with no evident sign of toxicity for the patients [116, 117].
Although ceramide accumulation in CF is clearly estab-
lished, in our opinion further studies are required in order
to consider amitriptyline as a pharmacological tool in CF.
The mechanism-based hypothesis of pH induced Cerami-
dase inactivation and acid Sphingomyelinase hyperactivity
is questionable (as above explained) and, to the best of
our knowledge, there are no data demonstrating either
a transcriptional or a posttranscriptional control of this
enzyme in vivo in CF or CF models. Data obtained from acid
Sphingomyelinase deficient mice are never accompanied by
an overview on the sphingolipid metabolism rearrangement
in thismodel nor are they characterized for any possible alter-
ation in their immune responses. The reported quantitations
of ceramide increase in CF mice versus wild type are also
puzzling, with an approximately 8-fold increase when mea-
sured by DAG Kinase total ceramide phosphorylation and
Thin Layer Chromatography separation [111, 115], compared
with mass spectrometry analytical methods (around 20–30%
increase) [92, 100]. Prolonged treatment with amitriptyline
(6 months) was performed on CF mice, monitoring the
reduced level of ceramide, but there are no data on the
response to infection and on the overall immune response
of the treated animals [111]. Finally, the requirement for acid
Sphingomyelinase activation in macrophages and immune
cells (i.e., ROS production and bactericidal activity [106]), to
give rise to proper signaling during infection, leaves an open
question as to the efficacy of this treatment in patients with
chronic infections.
An alternative explanation of sphingolipid metabolite
imbalance in CF is derived from studies conducted by
Wargall’s group and our own. It relies on the hypothesis
that CFTR deficiency induces intracellular stress leading to
an upregulation of the rate-limiting step of sphingolipid de
novo synthesis, with consequent accumulation of ceramide.
Since an intracellular increase of ceramide stimulates Sph-
ingomyelinases (as effectively as TNF𝛼), thereby amplifying
the Sphingomyelinase activation [44], this mechanism may
also explain the effect of amitriptyline administration in
CF models. By means of radioactive precursor treatment
(3H serine and 3H sphinganine), elegant metabolism studies
revealed that sphingolipid synthesis is significantly enhanced
in IB3 CF epithelial cells compared to normal C38 cells:
increased rate of radioactivity incorporationwas assessed, for
de novo as well as the recycle path of ceramide synthesis and
for sphingomyelin synthesis.Moreover, amarkedly enhanced
expression of Serine Palmitoyl Transferase 1 subunit was
found in CF cells, and its expression inversely correlates
with CFTR expression in airway epithelial cells. The mass
of C16-dihydroceramide and C22- and C24-ceramide species
increased compared with controls, whereas C18-ceramide
andC18:1-ceramidesmass decreased [83]. Similar resultswere
obtained by our group comparing the same cell lines under
inflammatory stimulation: we concluded that TNF𝛼 was able
to significantly enhance Serine Palmitoyl Transferase 1 tran-
script in IB3 cells and that inflammatory cytokines transcrip-
tion and release, induced by TNF𝛼, were impaired by treating
cells with myriocin [92], the inhibitor of Serine Palmitoyl
Transferase (the rate-limiting enzyme in the sphingolipid de
novo synthesis pathway [13]). Next, we demonstrated that the
response againstP. aeruginosa acute lung infection inCFmice
is ameliorated by intratracheal treatment with myriocin and
that both ceramide and inflammatory mediators pulmonary
levels of these mice were corrected to those of wild type mice
[92].
Although enhanced sphingolipid synthesis in CF was
shown to induce ceramide and sphingomyelin mass increase,
the CFTR silenced human airway epithelial cell line exhib-
ited ∼60% lower GM1 ganglioside than control cells and
was unable to migrate, showing impaired activation of 𝛽1-
integrin, phosphorylation of focal adhesion kinase, and
Crk-associated substrate. Exogenously added GM1 partially
restored migration of CFTR silenced cells [118]. This defi-
ciency in gangliosidesmay be related to dysregulated intracel-
lular trafficking of neosynthesized ceramide andmay account
for reduced antibacterial responses, since gangliosides are
involved in bacteria interaction (as previously mentioned).
It should be noted that the loss of CFTR function leads to
altered cholesterol trafficking, resulting in increased choles-
terol synthesis. Excessive cholesterol causes pathological con-
ditions such as atherosclerosis. It is recognized that sterols can
modulate the levels of other lipids to attain lipid homeostasis;
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thus, excess free cholesterol may play a role in modulating
compensatory sphingolipid pathways [119] and it is suggested
that this perturbation in cholesterol regulation contributes to
the inflammatory response present in CF [120].
The overall data suggest that decreased CFTR expression
would reflect a state in which augmented membrane lipid
synthesis, including sphingolipids, is necessary to compen-
sate the dysfunction and maximally increase membrane
stability. This hyperanabolism state either associates with or
possibly promotes hyperinflammation, with ceramide being a
major signalingmediator.This concept is further sustained in
the following paragraph, dealing with sphingolipids involve-
ment in COPD pulmonary inflammation [83].
The evidence discussed above is summarized in Figure 2.
5.3. Chronic Obstructive Pulmonary Disease. Chronic
obstructive pulmonary disease (COPD) is an inflammatory
respiratory disease, estimated to become the third leading
cause of death worldwide by 2020, after ischemic heart
disease and cerebrovascular disease [121, 122]. The Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
defines COPD as follows: COPD, a common preventable
and treatable disease, is characterized by airflow limitation
that is usually progressive and associated with an enhanced
chronic inflammatory response in the airways and the
lung to noxious particles or gases. Exacerbations and
comorbidities contribute to the overall severity in individual
patients (global strategy for the diagnosis, management, and
prevention of chronic obstructive pulmonary disease: revised
2014; Global Initiative for Chronic Obstructive Lung Disease
(GOLD), available online: http://www.goldcopd.org/). Salvi
and Barnes, from population-based studies, proposed that
cigarette smoke is a risk factor only for approximately half
of COPD patients, and alternative genetic and epigenetic
environmental risk factors are clearly implicated in the
disease’s etiology. The triggering causes of COPD include
indoor and outdoor air pollution (i.e., biomass fuel, dust,
and fumes [123]). A central role in the pathophysiology
of COPD has been shown to be played by chronic
inflammation of the airways [124]. Although cause related,
the inflammation process characterizing COPD persists
long after cessation of stress (i.e., quit smoking) and relies
on cells and mediators ranging from innate to adaptive
immunity, ROS overproduction and induced damage,
imbalance of local proteolysis/antiproteolysis, fibrosis, and
altered angiogenesis. The outcome is a thickened (and also
dysfunctional) epithelial layer, increased thickness of the
smooth muscle layer of the airway, disruption of the alveolar
walls with varying levels of fibrosis, hypoxic vasoconstriction
[125], the narrowing and progressive loss of terminal
bronchioles and increased peripheral airway resistance,
and arterial hypertension [126]: all these features precede
emphysematous demise of the COPD lung structure [127].
Depending on the patients (age, susceptibility to infection,
etc.), hyperinflammation is conducive to an increase in the
number and size of mucus-secreting glands. Such condition,
named mucus metaplasia, causes mucus hypersecretion,
increased mucin stores in the epithelium according to
airflow limitations, and increased luminal mucus obstructing
the airways and evolves into chronic bronchitis [128]. Thus
chronic bronchitis and emphysema often overlap in COPD
patients, with the burden of one or the other prevailing.
Susceptibility to exacerbations is defined by background
inflammation in the lung tissue, microbiota equilibrium, and
comorbidities. Individual immune responsive ability and
autoimmunity have been indicated as possible initiators of
the pathologic inflammation of COPD [129]. Up to the 1960s,
the imbalance between proteases and antiproteases induced
during inflammation was ascribed as the major mechanism
initiating emphysema and COPD pathogenesis. In the last
decade, however, the collapsing of the alveolar structure was
explained in terms of apoptosis of epithelial and endothelial
cells and of excessive inflammatory stress. Interestingly,
autophagy was demonstrated to be significantly impaired,
with marked accumulation of p62-enriched vesicles in the
epithelia of COPD patients, accounting for accumulation
of damaged material and unbalanced homeostasis between
degradation and resynthesis [130, 131].
In line with this evidence, metabolic changes responsible
for proinflammatory metabolites accumulation can be con-
sidered as one of the triggering causes concurring in COPD
etiology: specifically, sphingolipid mediators contribute to
the inflammatory process, driving the onset and progression
of the pathology.
In 2005, Petrache and colleagues induced emphysema
in mouse lung by subcutaneous treatment with the VEGF
receptor 1 and receptor 2 inhibitor, SU5416. They demon-
strated that apoptosis was mediated by ceramide, whose
accumulation was localized at the alveolar septal cells and
not in bronchi, colocalized with caspase-3 activation and
most importantly preceded (by about twenty days) alveo-
lar enlarging and damage. The accumulation of ceramide
depended on its de novo synthesis and the authors were
able to prevent VEGFRs inhibitor-induced damage by sys-
temic administration of fumonisin B1 or myriocin. Indeed,
a later activation of acid Sphingomyelinase was found
in its secreted form, released as a feed-forward mecha-
nism in response to enhanced sphingolipids synthesis, thus
increasing the pool of paracellular ceramide and amplify-
ing lung inflammation and injury. Anti-ceramide antibody
i.p. administration was partially able to neutralize extra-
cellular ceramides and attenuated lung apoptosis, induced
by the VEGFR inhibitor. To better prove that the altered
sphingolipid metabolism severely affects lung physiology,
they administered fumonisin B1 to untreated normal mice
and observed alveolar enlargement and damage, which was
inhibited by replenishment of sphingoid bases (sphingosine-
1-phosphate and FTY720 combinatorial treatment, with the
aim of reintroducing sphingoid bases but simultaneously
downregulating the sphingosine-1-phosphate receptor 1 sig-
naling). FTY720 and exogenous sphingosine exert a protec-
tive effect on airspace enlargement, concomitant with attenu-
ation of VEGFR inhibitor-induced lung apoptosis, possibly
by decreasing the ceramide/sphingosine-1-phosphate ratio
(by FTY720 inhibition of Ceramide Synthesis and induction
of Sphingosine Kinase, resp.) [43]. Moreover, intratracheal
instillation of synthetic ceramide analogue C12 was able to
induce septal apoptosis and emphysema, by triggering the
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Figure 2: Sphingolipidsmodulation and bioactivity in cystic fibrosis: prevalent sphingolipids alteration in the alveolar lung compartment and
induced responses in endothelial cells (E), alveolar epithelial cells (alveolar type 1 AI, alveolar type 2, AII), macrophages (M), and neutrophils
(N). SPT, Serine Palmitoyl Transferase; Cer, ceramide; a SMase, acid Sphingomyelinase; SM, sphingomyelin; lyso-PC, lysophosphatidyl
choline; PGE, prostaglandin; S1P, sphingosine-1-phosphate; ROS, reactive oxygen species.
synthesis of long-chain endogenous ceramide, which accu-
mulated twofold [44]. As alveolar cell apoptosis and oxidative
stress mutually interact to mediate alveolar destruction [39],
the same research group demonstrated, shortly afterwards,
that intratracheal ceramide instillation decreased cytosolic
SOD activity and increased superoxide production in the
lungs. They also demonstrated that overexpressing human
Cu/Zn SOD in mice significantly protected from intratra-
cheal ceramide-induced superoxide production, apoptosis,
and air space enlargement. It is to be noted that the lung
activation of acid Sphingomyelinase, in response to ceramide
treatment, was abolished when overexpressing SOD. Such
evidence demonstrates that exogenous ceramide treatment
and the consequently stimulated endogenous neosynthe-
sized ceramide merge in ROS formation and acid Sphin-
gomyelinase activation. This latter activity amplifies injury
through redox-dependent mechanism. Both ROS accumu-
lation and acid Sphingomyelinase derived ceramide are the
major effectors of the damage, leading to the conclusion
that enhanced neosynthesis of lung ceramides is upstream
of redox-dependent inflammatory damages [132]. Knowing
that cigarette smoke induces oxidative stress and is one of
the causes of emphysema, mass spectrometry analysis proved
that cigarette smoke is able to induce ceramide accumula-
tion in the murine lung [132]. Accordingly, lung ceramide
levels were markedly higher in patients with emphysema
due to chronic cigarette smoking compared with patients
without emphysema, as measured by Diacylglycerol Kinase
assay, followed byThin Layer Chromatography and ceramide
quantitation. Immunohistochemistry revealed that ceramide
was almost exclusively localized to alveolar septal cells and
alveolar macrophages. Human emphysematous lungs exhibit
a significant increase in long-chain ceramides. Even smoking
alone (without a pathological diagnosis of emphysema)
changed the lung ceramide expression profile, suggesting that
not only absolute levels but also patterns of ceramide species
expressionmay be upregulated and contribute to emphysema
induction. These studies highlight the concept that ceramide
accumulates in specific lung compartment and there induces
damage in epithelial cells, which in turn supports inflam-
mation in a vicious loop. Ceramide accumulation results
from deregulation of sphingolipid metabolism. The accu-
mulation of newly synthesized sphingolipids (bearing long
acyl chains) leads to the extracellular release of ceramide(s).
In addition, an increased synthesis of catabolism enzymes,
such as Sphingomyelinases, is required in response to the
sphingolipids accumulation, and eventually the extracellular
release of these enzymes occurs too. These events are linked
to prolonged extracellular inflammatory/damaging signal-
ing [44]. Levy and colleagues substantiated the hypothe-
sis that cigarette smoke induces the activation of neutral
Sphingomyelinase 2 and apoptosis in human respiratory
epithelial cells and glutathione administration was able to
inhibit apoptosis [133]. Mice exposed to cigarette smoke
exhibit a twofold increase in lung ceramide (measured by
DiacylglycerolKinase assay) aswell as a significant increase in
neutral Sphingomyelinase expression (evaluated by immune
histochemical staining of the protein with noncommercial
antibodies), both in the bronchial epithelium and in alveolar
septal cells. Diet supplementation with N-acetyl-cysteine
(glutathione precursor), or intranasal installation of biotin-
labeled neutral Sphingomyelinase 2 siRNA, showed a signifi-
cant reduction in this enzyme staining and of lung apoptosis,
measured both by TUNEL assay and by evaluation of cleaved
caspase-3 levels. Immunostaining for neutral Sphingomyeli-
nase 2 on lung biopsies from emphysematous smoker patients
versus healthy people showed an enhanced expression of
the enzyme [134]. Finally, the oncogene product Src Kinase
was shown to activate the serine kinase p38, responsible for
phosphorylation and activation of neutral Sphingomyelinase
2, upon oxidative stress [135].
The catabolism of ceramide gives rise not only to sph-
ingosine but also to the opposing bioactive sphingosine-
1-phosphate, known to promote proliferation and survival,
even though in very low intra- or extracellular concentra-
tion [43]. Systemic administration of sphingosine, via daily
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intraperitoneal injection, increased sphingosine-1-phosphate
levels in a dose-dependentmanner. In the presence ofVEGFR
blockade, stimulation of sphingosine-1-phosphate activity, by
either administering its precursor D-erythro-sphingosine or
the agonist of its receptor 1, SEW2871, led to a decrease in
the ceramide to sphingosine-1-phosphate ratio and markedly
reduced apoptosis and lung injury [43].
Sphingosine-1-phosphate receptors 1–3 (S1PRs) are
involved in the control of pulmonary vascular function
by altering endothelial and epithelial barriers as well as
smooth muscle cell function [48, 136, 137]. In mice, S1PR3
receptor activation induced pulmonary edema by opening
narrow junctions between alveolar type I and type II cells
[137], and S1PR2 deficient mice and mice with reduced S1P3
receptor expression were protected against LPS-induced
disruption of the alveolar barrier [136, 137]. A recent report,
analyzing the expression of the genes related to sphingosine-
1-phosphate synthesis/degradation and of its receptors
in human lung, showed that relative mRNA expression
of S1PR5 was significantly reduced in COPD patients
compared with control [138]. A possible scenario in which
different S1PRs are differentially modulated in the airways
to promote inflammation can be envisaged from these
reports.
Environmental stresses, including cigarette smoke and
hypoxia, and chronic inflammation have recently been shown
to reduce CFTR function, and this suggests that common
mechanisms contribute to the progression of both CF and
COPD [114]. Immune histochemical analysis of tissue sec-
tions reveals that CFTR expression is inversely correlated
with the severity of emphysema and with ceramide accu-
mulation in COPD subjects, compared with control subjects
[84]. Bodas and colleagues also demonstrated that acute
exposure to cigarette smoke induces a significant downreg-
ulation of CFTR in lung and in particular in membrane
rafts. From antibody staining, they claim that the absence of
CFTR in rafts induces the accumulation of ceramides within
the membrane, possibly as a compensatory mechanism for
the altered stability of the membrane [84]. Although it is
risky to draw conclusions on ceramide levels from quanti-
tation obtained by staining with anti-ceramide antibodies,
these data are in line with other published results, which
suggest that deficiency of CFTR switches on an “alarm”
mechanism that leads the cell to modulate the synthesis of
membrane components [83]. In this view, an upregulation of
sphingolipid synthesis not only fulfills the requirement for
supporting raft anomalies but also triggers an alarm signal
that evolves toward a chronic inflammatory state.
Treatment with CFTR inhibitors GlyH-101 and
CFTR(inh)-172 caused a dose-dependent increase in human
and rat pulmonary endothelial monolayer permeability,
redistribution of the junctional protein 𝛽-catenin, and
scattered actin stress fiber formation. Endothelial cells
treated with exogenous sphingosine-1-phosphate or with
endogenous sphingosine-1-phosphate lyase inhibitor
exhibited a significantly smaller decrease in permeability
in response to CFTR inhibition. In this model, exposure to
cigarette smoke markedly enhanced the loss of endothelial
barrier function [90].
To the degree that the catabolism of ceramide gives
rise to sphingoid bases and these become phosphory-
lated to produce sphingosine-1-phosphate, the metabolism
of ceramide via direct phosphorylation forms ceramide-
1-phosphate, another metabolite opposing ceramide and
signaling towards proliferation and survival. In a recent
publication, ceramide-1-phosphate (bearing either the short
chain analogous C8 acyl chain or the C16 natural acyl chain)
was administrated intratrachea.The administration occurred
after acute cigarette smoke inflammation or it lasted for the
last three months, overlapping with the last part of a seven-
month cigarette smoke treatment (long treatment to model
chronic inflammation). Ceramide-1-phosphate significantly
reduced inflammation (cytokines lung expression and BAL
infiltrate) as well as alleviating lung emphysema occurring
after chronic stress [52]. Ceramide-1-phosphate effects were
recapitulated in vitro, blocking cigarette smoke induced
hyperinflammation in human airway epithelial cells and
neutrophils from COPD patients [52].
It is intriguing to note that the above reported data suggest
that ceramide-1-phosphate and sphingosine-1-phosphate,
known to modulate inflammation with different mecha-
nisms and outcomes, may be applied in pulmonary chronic
inflammatory disease with a mere anti-inflammatory action.
Our hypothesis is that, in stress conditions such as chronic
inflammation, the ER major and ubiquitous cellular sensors
stimulate de novo synthesis of ceramides as an intrinsic
response to the stress, affecting the whole network of the sph-
ingolipid metabolism, leading to membrane reorganization
and signaling modulation. In order to balance the increased
signaling of ceramide, its opposite metabolites ceramide-1-
phosphate and sphingosine-1-phosphate, even if present at
lower concentrations than the ceramide, may be able to
counteract ceramide-induced outcomes. Thus the bioactivity
of ceramide should rather be considered not per se but as a
ceramide/ceramide-1-phosphate or ceramide/sphingosine-1-
phosphate ratio. It is also necessary to take into account the
possibility of ceramide-forming sphingosine, which can be
considered as proinflammatory “lyso-ceramides,” in oppo-
sition to forming sphingomyelin and glycosphingolipids.
This complex picture might be envisaged for therapeutic
approaches, although requiring much more thorough trans-
lational studies.
Lung chronic disease is to be considered as a systemic
inflammatory disease and medical research focuses on the
identification of early new markers in blood and body
fluids [139, 140]. A massive presence of neutrophilic infil-
trate along with increased inflammatory mediators signaling
(i.e., IL-6) has been detected in the sputum of patients
with COPD [141] as well as in bronchoalveolar lavage fluid
(BALF) [142]. Bahr and colleagues studied the peripheral
blood mononuclear cells expression profile in 136 subjects
of the COPD gene cohort. Among others they found an
overexpression of acid ceramidase in COPD and emphysema
patients but not in those with chronic bronchitis. Looking
for metabolites, to validate the gene expression results, they
found an accumulation of lactosyl ceramide. The authors
did not clearly explain the link between the enzyme and the
metabolite [143]; anyhow these evidences confirm the spread
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of inflammation. One year later, the analysis of sputum
samples demonstrated that there was an increase in different
sphingolipids species (ceramides, sphingomyelin, and gan-
gliosides) in smoking compared with nonsmoking COPD
patients. Specifically, ceramide concentration is inversely
related to the severity of the disease. A part of these
sphingolipids was significantly reduced upon cessation of
smoking [144]. A hypothesis for these apparently contrasting
data was launched in a recent large-scale study of more
than 250 subjects from the COPD gene cohort, demon-
strating that plasma sphingomyelin, ceramide, ganglioside
GM3, monohexosyl ceramide, and sphingosine-1-phosphate
levels inversely correlated with COPD worsening phenotype
(low FEV1) and emphysema, whereas trihexosylceramides
correlated directly with exacerbations. In agreement with
previous data from peripheral blood mononuclear cells, no
correlation with chronic bronchitis phenotype was traced.
Plasma sphingolipids may derive from shed cellular plasma
membrane, apoptotic bodies,microvesicles, or exosomes.The
decreased levels of sphingomyelin in plasma were ascribed to
increased catabolism activities by enhanced/activated plasma
secreted acid Sphingomyelinase and neutral Ceramidase [74,
145]. These data suggest that, in severe COPD and its exac-
erbations, plasma accumulation of sphingolipid catabolites
and related secreted enzymes possibly contributes to systemic
inflammation [146].
An impairment of apoptotic cell phagocytosis in emphy-
sema lungs, leading to secondary necrosis and promoting
inflammation, has been reported [147, 148]. Being a regula-
tor of autophagy, ceramide lung enrichment may interfere
with autophagosomes clearance. Intratracheal instillation of
ceramide (PEG-C16-ceramide) after intrapulmonary intro-
duction of apoptotic (PI-targeted) human thymocytes sig-
nificantly decreased the phagocytic uptake of the exogenous
cells by alveolar macrophages, recovered from BAL [149].
The authors conclude that, upon occurrence of inflammatory
events, such as the exogenous ceramide instillation, endoge-
nous ceramide accumulates and gives rise to sphingoid bases
that are primarily responsible for phagocytosis inactivation:
alveolar macrophages recovered their phagocytic ability,
impaired by cigarette smoke extracts, when pretreated with
myriocin (to inhibit de novo synthesis of sphingolipids) or
MAPP or siRNA to inhibit acid ceramidase but not with
fumonisin B1 (to inhibit sphingosine acylation) nor Sph-
ingomyelinase inhibitors [149]. Moreover, the sphingosine
intracellular increase caused by exposure to cigarette smoke
was responsible for an altered lipid raft assembling, impairing
the presence in the membrane of Rac1 GTPases, which
promotes membrane ruffling and phagosome closure [149].
Emphysema is caused by alveolar structure demise. This
destructive process particularly targets lung microvascu-
lar endothelial cells and alveolar epithelial cells. Besides
apoptosis, aberrant lung endothelial cell responses may
contribute to pulmonary vascular remodeling, frequently
observed in COPD in response to the low oxygen level
caused by terminal bronchiolar loss, favoring endothelia
permeability and inflammation [150, 151]. Petrache’s group
conducted an interesting study using primary human lung
microvascular endothelial cells derived from smokers or
nonsmoking healthy subjects. Following the hypothesis that
ceramide synthesis is increased upon exposure to smoke and
that this ceramide is released and acts paracellularly, they
treated endothelial cells with palmitoyl ceramide (Cer16).
While cells from nonsmokers responded with apoptosis, the
smoker-derived cells were found to be resistant to exogenous
ceramide and exhibited marked proliferation and increased
autophagy. This involved a baseline-increased phosphory-
lation of Akt (a known prosurvival kinase, inhibited by
ceramide and possibly enhanced as a feed-forward mecha-
nism in an environment with baseline-increased ceramide)
and increased levels of high-mobility group box 1 (an inflam-
matory protein, elevated in sputum and plasma of COPD
patients and directly involved in vasculature remodeling in
emphysema [150]). The authors hypothesize that deregulated
sphingolipid metabolism and increased endogenous sphin-
gosine, arising from increased ceramide production, may
contribute to inflammation by promoting the expression
and the activity of high-mobility group box 1 and aberrant
vasculogenesis.
A correlation between lactosyl ceramide accumula-
tion and increasing severity of emphysema was found in
lung tissues from COPD subjects and in cigarette smoke
treated mice lungs. The increase in this sphingolipid was
impaired by pharmacological inhibition of lactosyl Ceramide
Synthase. Moreover, in bronchial-epithelial cells (BEAS2B)
and macrophages (Raw264.7), lactosyl Ceramide Synthase
inhibitors impaired aberrant-autophagy (p62-accumulation)
and apoptosis induced by cigarette smoke extracts [152].
Overall, the evidence cited above (summarized in
Figure 3) traces an important role for ceramide synthesis and
its derived metabolites in sustaining chronic lung inflamma-
tion.
6. Conclusions
Sphingolipid molecules play an active part in the extracellu-
lar equilibrium of proinflammatory and anti-inflammatory
lipids which finely regulate mucosal activities and immunity
in the lungs. In addition to being structural membrane
components and endogenous mediators, sphingolipids exert
an additional paracrine signaling role which is required for
physiological immune response, defense from pathogens,
and inflammation resolution. Deregulation of sphingolipid
mediator homeostasis alters the development of the fetal
lung and impairs its maturation and functionality. In adult
life, deregulation of sphingolipid mediators is associated with
a derangement of the inflammatory cascade. As outlined
above, a major distinction can be traced between the roles
of sphingolipids in acute and chronic lung inflammation.
Acute inflammation is triggered by a robust and sudden
stress, which sets off the rapid formation of alarm signals.The
hydrolysis of membrane sphingomyelin is primarily involved
in this external incident-intracellular response setting. Local
ceramide increase produced by Sphingomyelinases activates
different pathways cooperating in the activation of immune
defense, cell stress response, and eventually apoptosis in case
of cell failure. Chronic inflammation, on the other hand, is
per se the cause of a prolonged hidden and borderline stress,
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Figure 3: Sphingolipids modulation and bioactivity in COPD: prevalent sphingolipids alteration in the alveolar lung compartment and
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which alters cell features and eventually tissue physiology and
function. In this scenario, as a consequence of either a genetic
defect or environmental toxic factors such as pollutants, the
whole sphingolipid metabolic network undergoes a stable
shift requiring transcriptional regulation. An overall increase
in sphingolipid synthesis, coordinated with that of other
lipids devoted to forming surfactant, reflects an attempt to
enhance mucosal protection. This is a fragile equilibrium
that may be compromised if an additional external insult,
such as an infection, supervenes; the equilibrium can then
collapse into a self-sustaining hyperinflammatory reaction,
and the upregulation of the metabolic rate itself turns out to
be a pathogenetic rather than protective adjustment. Insofar
as this picture is correct, the goal of future translational
research must be to obtain a preventive, disease-personalized
medicine, targeting the alteration of metabolism induced by
the disease. Within the lung, sphingolipid metabolism may
constitute a key target because sphingolipid synthesis and
ceramide levels seem to control the synthesis of other lipid
mediators involved in inflammation, and ceramide modu-
latory agents have a profound biological effect in processes
such as epithelial apoptosis, endothelial permeability and
immune cells mobilization, mucus production, and pathogen
clearance.
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